PSMA-Targeted Therapy Market Set for Significant Growth Through 2036 Across 7MM

DelveInsight's "Prostate-Specific Membrane Antigen (PSMA) Targeted Therapy - Target Population, Competitive Landscape, and Market Forecast - 2036" report delivers an in-depth understanding of PSMA-targeted therapy, historical and forecasted competitive landscape, as well as the PSMA-targeted therapy market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the PSMA-targeted therapy market outlook, drug uptake, treatment scenario, and competitive landscape, Click here: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the PSMA-Targeted Therapy Market Report:
• The PSMA-targeted therapy market size is expected to grow at a significant CAGR during the study period (2022-2036), with the United States holding the largest market share among the 7MM in 2024.
• PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) generated approximately USD 1,392 million in revenue globally in 2024, achieving blockbuster status. In March 2025, Novartis announced FDA approval of the expanded use of PLUVICTO for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
• In February 2026, Curium together with PeptiDream and PDRadiopharma announced that the first patient has been dosed in the registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA-positive mCRPC.
• In January 2026, Telix announced that the first patient has been dosed in the Phase III registration study of TLX591-Px (ILLUCCIX) for prostate cancer imaging in Japanese patients, dosed at Shonan Kamakura General Hospital in Kamakura, Japan.
• In May 2025, Lantheus discontinued development of PNT2002 after final SPLASH data showed no overall survival benefit, leaving Novartis's PLUVICTO dominant in the pre-chemotherapy mCRPC setting.
• In April 2023, the FDA granted Fast Track designation to 177Lu-PNT2002 for the treatment of patients with metastatic castration-resistant prostate cancer.
• In 2022, the FDA approved PLUVICTO as the first PSMA-targeted therapy for adult patients with PSMA-positive mCRPC previously treated with androgen receptor pathway inhibitors and taxane-based chemotherapy.
• Key epidemiology findings: in 2025, the total five-year prevalence of prostate cancer was nearly 2,800,000 across the 7MM, with the US accounting for approximately 1,160,000 five-year prevalent cases. In 2025, there were approximately 70,000 total cases of metastatic castration-sensitive prostate cancer (mCSPC) and 54,000 prevalent cases of mCRPC in the US.
• The most common age group for prostate cancer is 65-74 years, with 190,000 age-specific cases reported in Japan in 2025 for this group alone.
• The growing focus of major players including Novartis, Curium, Telix Pharmaceuticals, AstraZeneca, and Lantheus on next-generation PSMA radiopharmaceuticals - spanning alpha-emitters, radioimmuno-conjugates, and novel small molecules - is expected to drive continued market expansion and challenge current market dynamics through 2036.
• Key PSMA-Targeted Therapy Companies: Novartis, Curium, Telix Pharmaceuticals, AstraZeneca, Lantheus, and others.
• Key PSMA-Targeted Therapy Drugs: PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), 177Lu-PSMA-I&T, 177Lu-DOTA-rosopatamab tetraxetan (TLX591), FPI-2265, and others.
• The PSMA-targeted therapy market is expected to surge due to rising prostate cancer prevalence, the expanding pipeline of next-generation radiopharmaceuticals, and the superior precision of PSMA-targeted delivery over conventional chemotherapy and radiation.

PSMA-Targeted Therapy Overview
Prostate-Specific Membrane Antigen (PSMA) is a protein highly expressed on the surface of prostate cancer cells but minimally present in normal tissues. PSMA-targeted therapy is an advanced form of cancer treatment that uses a radioactive tracer to selectively seek out and destroy PSMA-expressing cells, thereby reducing side effects commonly associated with traditional chemotherapy or radiation therapy.
While PSMA-targeted therapy does not cure cancer, its primary goals are to relieve symptoms, reduce tumor size, and slow disease progression. It is typically offered after patients have undergone other standard treatments such as surgery, radiation, hormone therapy, or chemotherapy. Treatment involves IV injection of a standard dose every six weeks, for a total of six sessions over approximately 36 weeks, with blood tests conducted between each session to monitor response.

Get a Free Sample for the PSMA-Targeted Therapy Market Report: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

PSMA-Targeted Therapy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted patient pool across the 7MM from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders, and provides a detailed analysis of the eligible and treated patient population across prostate cancer stages.

PSMA-Targeted Therapy Epidemiology Segmentation:
The PSMA-Targeted Therapy market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Cases in Selected Indications for PSMA-Targeted Therapy
• Total Eligible Patient Pool in Selected Indications for PSMA-Targeted Therapy
• Total Treated Cases in Selected Indications for PSMA-Targeted Therapy

Download the report to understand which factors are driving PSMA-Targeted Therapy patient pool and market trends @ PSMA-Targeted Therapy Epidemiology and Market Forecast: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

PSMA-Targeted Therapy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of approved and emerging PSMA-targeted therapies expected to be launched during 2022-2036. The analysis covers market uptake by drug, patient uptake by therapy, and sales across the 7MM.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind maximal adoption, comparing drugs based on market share. The report also covers PSMA-Targeted Therapy Pipeline Development Activities - providing detailed information on collaborations, acquisitions and mergers, licensing, and patent details - alongside a clinical trials analysis covering candidates in Phase III, Phase II, and Phase I. Strategic collaborations such as the Lantheus-Point Biopharma exclusive license agreement for PNT2002, involving an initial payment of USD 250 million and potential milestones exceeding USD 1.5 billion, exemplify the investment momentum in this space.

PSMA-Targeted Therapy Drugs and Key Companies
• PLUVICTO (lutetium Lu 177 vipivotide tetraxetan): Novartis - FDA approved 2022 (US, EU); JP approved 2025; indicated for PSMA-positive mCRPC post-ARPI and taxane-based chemotherapy
• 177Lu-PSMA-I&T: Curium - Phase III (ECLIPSE trial); registrational trial initiated in Japan (February 2026) for PSMA-positive mCRPC
• 177Lu-DOTA-rosopatamab tetraxetan (TLX591): Telix Pharmaceuticals - Phase III; radioimmuno-conjugate targeting PSMA with lutetium-177; Phase III imaging study initiated in Japan (January 2026)
• FPI-2265: AstraZeneca - Phase II (TATCIST/AlphaBreak trial); actinium-225-based alpha-emitting PSMA-targeting radioconjugate for mCRPC, including patients pre-treated with 177Lu-based PSMA therapy

Discover more about therapies set to grab major PSMA-Targeted Therapy market share @ PSMA-Targeted Therapy Treatment Market https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

PSMA-Targeted Therapy Market Drivers
• Rising global incidence and prevalence of prostate cancer expanding the eligible patient population for PSMA-targeted radioligand therapy
• Proven clinical efficacy of PLUVICTO demonstrated improved overall survival and radiographic progression-free survival in the VISION trial driving physician confidence and adoption
• Robust pipeline of next-generation PSMA agents including 177Lu-PSMA-I&T, TLX591, and alpha-emitter FPI-2265 set to broaden treatment options and address earlier lines of therapy
• Superior targeting precision over conventional chemotherapy, reducing off-target toxicity and improving patient quality of life
• Expanding regulatory approvals and geographic market entries including Japan launches in 2025-2026 driving 7MM market growth
• Active R&D investment and strategic collaborations among major players fueling clinical development and manufacturing scale-up of radiopharmaceutical supply chains

PSMA-Targeted Therapy Market Barriers
• High treatment costs and specialized radiopharmaceutical manufacturing and delivery infrastructure limiting broad geographic accessibility
• PSMA-PET confirmation required prior to treatment, potentially excluding PSMA-low or PSMA-negative patients from eligibility
• Reimbursement challenges in key markets notably the UK's NICE non-recommendation for PLUVICTO creating access disparities across the 7MM
• Emerging resistance mechanisms and tumor heterogeneity that may reduce long-term treatment efficacy, necessitating combination strategies

Scope of the PSMA-Targeted Therapy Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key PSMA-Targeted Therapy Companies: Novartis, Curium, Telix Pharmaceuticals, AstraZeneca, Lantheus, and others
• Key PSMA-Targeted Therapy Drugs: PLUVICTO, 177Lu-PSMA-I&T, TLX591, FPI-2265, and others
• PSMA-Targeted Therapy Assessment: Current marketed and emerging PSMA-targeted therapies across prostate cancer indications
• PSMA-Targeted Therapy Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, market entry strategies
• PSMA-Targeted Therapy Unmet Needs, KOL Views, Analyst Views, Market Access, and Reimbursement

Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.